Bank of New York Mellon Corp Buys 44,584 Shares of Genelux Co. (NASDAQ:GNLX)

Bank of New York Mellon Corp grew its position in Genelux Co. (NASDAQ:GNLXFree Report) by 476.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 53,938 shares of the company’s stock after purchasing an additional 44,584 shares during the period. Bank of New York Mellon Corp’s holdings in Genelux were worth $1,321,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. California State Teachers Retirement System bought a new position in shares of Genelux in the second quarter valued at approximately $30,000. Tower Research Capital LLC TRC purchased a new position in shares of Genelux during the first quarter worth approximately $32,000. American International Group Inc. purchased a new position in shares of Genelux in the second quarter worth $44,000. JPMorgan Chase & Co. increased its stake in shares of Genelux by 2,105.0% in the second quarter. JPMorgan Chase & Co. now owns 2,205 shares of the company’s stock worth $72,000 after buying an additional 2,105 shares during the period. Finally, Citigroup Inc. bought a new stake in Genelux in the first quarter valued at $84,000. Hedge funds and other institutional investors own 10.77% of the company’s stock.

Analysts Set New Price Targets

GNLX has been the topic of a number of research reports. Brookline Capital Management upgraded shares of Genelux from a “hold” rating to a “buy” rating in a report on Monday, October 30th. Benchmark dropped their price target on Genelux from $38.00 to $30.00 and set a “speculative buy” rating for the company in a research note on Friday, November 24th. Finally, HC Wainwright assumed coverage on Genelux in a report on Monday, November 27th. They set a “buy” rating and a $35.00 price target on the stock.

View Our Latest Stock Report on Genelux

Insider Activity

In other Genelux news, VP Yong Yu sold 36,800 shares of the stock in a transaction dated Thursday, December 7th. The stock was sold at an average price of $11.85, for a total value of $436,080.00. Following the sale, the vice president now owns 32,535 shares of the company’s stock, valued at approximately $385,539.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, VP Yong Yu sold 36,800 shares of the firm’s stock in a transaction that occurred on Thursday, December 7th. The stock was sold at an average price of $11.85, for a total transaction of $436,080.00. Following the transaction, the vice president now owns 32,535 shares in the company, valued at approximately $385,539.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director John Thomas sold 9,000 shares of the firm’s stock in a transaction that occurred on Wednesday, December 13th. The stock was sold at an average price of $13.38, for a total value of $120,420.00. Following the transaction, the director now owns 463,460 shares in the company, valued at approximately $6,201,094.80. The disclosure for this sale can be found here. Corporate insiders own 11.70% of the company’s stock.

Genelux Stock Up 11.2 %

Shares of GNLX stock opened at $9.37 on Friday. The stock’s 50-day moving average is $12.56 and its 200 day moving average is $17.78. Genelux Co. has a 1-year low of $5.51 and a 1-year high of $40.98.

Genelux (NASDAQ:GNLXGet Free Report) last announced its quarterly earnings results on Tuesday, November 14th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.08). On average, analysts forecast that Genelux Co. will post -1.1 EPS for the current fiscal year.

About Genelux

(Free Report)

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer.

Further Reading

Want to see what other hedge funds are holding GNLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Genelux Co. (NASDAQ:GNLXFree Report).

Institutional Ownership by Quarter for Genelux (NASDAQ:GNLX)

Receive News & Ratings for Genelux Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genelux and related companies with MarketBeat.com's FREE daily email newsletter.